Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 14/20 | 0.43 |
| ▸ | PRKDC | P78527 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | IDE | P14735 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | GCKR | Q14397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11909224 | 0.83 | MAP2K3 (0.51) | ATRPRKDCMAP2K3KDM4E | |
| SCHEMBL11909211 | 0.80 | CCR1 (0.50) | ATRMAP2K3KDM4EP4HA1P4HTM | |
| SCHEMBL11908996 | 0.77 | MAP2K3 (0.43) | ATRMAP2K3P4HA1P4HTM | |
| SCHEMBL11907535 | 0.77 | MAP2K3 (0.43) | ATRMAP2K3P4HA1P4HTM | |
| SCHEMBL11908336 | 0.76 | ATR (0.42) | ATRPRKDCMAP2K3KDM4EP4HA1 | |
| SCHEMBL11909990 | 0.76 | MAP2K3 (0.40) | MAP2K3KDM4EP4HA1P4HTM | |
| SCHEMBL11909565 | 0.76 | ATR (0.55) | ATRPRKDCMAP2K3ATM | |
| SCHEMBL11906982 | 0.75 | MAP2K3 (0.44) | ATRPRKDCMAP2K3KDM4EP4HA1 | |
| SCHEMBL11907922 | 0.73 | KMT2A (0.45) | MAP2K3KDM4EP4HA1P4HTMGCK | |
| SCHEMBL11908032 | 0.72 | MAP2K3 (0.53) | MAP2K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ATR 423/4885PRKDC 9/4885PTGDR2 2996/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ATR 423/4885PRKDC 9/4885PTGDR2 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.